0HRT Stock Chart & Stats
$0.02
-$0.01(-33.44%)
At close: 4:00 PM EDT
$0.02
-$0.01(-33.44%)
Day’s Range― - ―
52-Week Range$0.02 - $0.05
Previous CloseN/A
Volume80.00
Average Volume (3M)0.00
Market Cap
$1.92M
Enterprise Value$5.97M
Total Cash (Recent Filing)$266.00K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding225,829,130
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap3.11
Enterprise Value/Revenue0.47
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda-4.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Gross MarginA roughly 49% gross margin has remained relatively steady in TTM and 2025, showing product economics have not deteriorated despite weaker sales. Preserving gross profit per dollar can support recovery if distribution and demand improve.
Product InnovationProducts launched since January 2023 generated 44% of Q2 net revenue, while the PlusHLTH portfolio and dedicated e-commerce platform broaden the offering. This indicates active development and creates avenues for repeatable growth beyond the legacy range.
Cost DisciplineOperating expenses fell 11.3% year over year to $1.7 million in Q2, demonstrating the company can adjust its cost base as revenue weakens. Continued discipline could slow losses and improve operating leverage if new products gain traction.
Bears Say
Revenue ContractionTTM revenue fell about 27.1% year over year and Q2 revenue declined 17.5%, showing contraction across periods rather than a single-quarter setback. A shrinking top line reduces scale benefits and makes fixed costs harder to absorb.
Persistent LossesThe company remains unprofitable, with a TTM net margin of about -15.7% and negative operating profitability; Q2 operating loss widened to $0.3 million. Persistent losses consume equity and constrain internally funded investment.
Negative Cash GenerationTTM operating cash flow was about -$0.49 million and free cash flow about -$0.52 million, continuing the outflow pattern from 2024–2025. Ongoing cash burn means growth and obligations may require external capital if profitability does not recover.
CV Sciences News
0HRT FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest share price was $0.02 and its highest was $0.05 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $1.92M.
When is CV Sciences Inc’s upcoming earnings report date?
CV Sciences Inc’s upcoming earnings report date is Nov 16, 2026 which is in 15 days.
How were CV Sciences Inc’s earnings last quarter?
CV Sciences Inc released its earnings results on Aug 17, 2026. The company reported -$0.004 earnings per share for the quarter.
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 225,829,130 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
CV Sciences Inc reported an EPS of -$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in GB:0HRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
0HRT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.View all GB:0HRT earnings summariesTechnical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―










